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Abstract
Background: Some studies have suggested that the suppression of endogenous LH secretion does
not seem to affect the majority of patients who are undergoing assisted reproduction and
stimulation with recombinant FSH (r-FSH). Other studies have indicated that a group of
normogonadotrophic women down-regulated and stimulated with pure FSH preparations may
experience low LH concentrations that compromise the IVF parameters. The present study aimed
to compare the efficacy of recombinant LH (r-LH) supplementation for controlled ovarian
stimulation in r-FSH and GnRH-agonist (GnRH-a) protocol in ICSI cycles.
Methods: A total of 244 patients without ovulatory dysfunction, aged <40 years and at the first
ICSI cycle were divided into two groups matched by age according to an ovarian stimulation
scheme: Group I (n = 122): Down-regulation with GnRH-a + r-FSH and Group II (n = 122): Down-
regulation with GnRH-a + r-FSH and r-LH (beginning simultaneously).
Result(s):  The number of oocytes collected, the number of oocytes in metaphase II and
fertilization rate were significantly lower in the Group I than in Group II (P = 0.036, P = 0.0014 and
P = 0.017, respectively). In addition, the mean number of embryos produced per cycle and the mean
number of frozen embryos per cycle were statistically lower (P  = 0.0092 and P  = 0.0008,
respectively) in Group I than in Group II. Finally the cumulative implantation rate (fresh+thaw ed
embryos) was significantly lower (P = 0.04) in Group I than in Group II. The other clinical and
laboratory results analyzed did not show difference between groups.
Conclusion: These data support r-LH supplementation in ovarian stimulation protocols with r-
FSH and GnRH-a for assisted reproduction treatment.
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Background
The pharmacology of ovarian stimulation has been
strongly influenced by the two-cell, two-gonadotrophin
theory [1] while, historically, follicular stimulation proto-
cols have included both luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) in an attempt to
mimic normal physiology [2]. During recent years, the
effect of LH on follicular maturation and pregnancy out-
come during the course of ovarian stimulation in relation
to assisted reproduction has received increasing attention.
This interest reflects the fact that modern stimulation pro-
tocols have resulted in substantially lower LH concentra-
tions than those observed in the natural cycle and in
previously used protocols. The introduction of gonado-
trophin-releasing hormone agonists (GnRH-a) in the
mid-1980s successfully circumvented the problems of a
premature LH surge. There has also been a gradual shift
from human gonadotrophin (HMG) with equal amounts
of FSH and LH-like activity over pure urine-derived FSH
preparations to recombinant human FSH (r-FSH), with-
out LH activity [3].
Some studies have suggested that the suppression of
endogenous LH secretion does not seem to affect the
majority of patients who are undergoing assisted repro-
duction and stimulation with r-FSH. Other studies have
indicated that a group of normogonadotrophic women
down-regulated and stimulated with pure FSH prepara-
tions may experience low LH concentrations that compro-
mise the parameters of the IVF treatment [3].
According to current concepts in folliculogenesis, LH
plays an essential role in the final stages of follicular mat-
uration [4,5]. Once an appropriate stage of follicular
development has been achieved in response to FSH treat-
ment, granulosa cells become receptive to LH stimulation,
and LH becomes capable of exerting its actions on both
theca cells and granulosa cells. In fact, at non-saturating
concentrations of FSH and LH, the response is additive.
Moreover, it has been postulated that the maturing follicle
reduces its dependence on FSH by acquiring LH receptors
[4,5]. Thus, LH may play an essential role in determining
oocyte maturity and development potential in IVF cycles.
However, exposure of the developing follicle to inappro-
priately high concentrations of LH may interfere with fol-
licular and oocyte maturation and thus adversely affect
the reproductive process [6,7].
The present study aims to compare the efficacy of recom-
binant LH (r-LH) supplementation in women undergoing
assisted reproduction and stimulation with r-FSH in the
GnRH-a protocol of ovarian stimulation in ICSI cycles.
Methods
This was a retrospective, observational study including a
total of 244 patients without any ovulatory dysfunction,
aged <40 years and at the first ICSI cycle. The data were
collected from the medical records at the Centre for
Human Reproduction Prof Franco Jr. between January
2005 and July 2007. All the patients signed terms of
informed consent before the fertilization treatment grant-
ing use of their data for scientific purposes, with the pro-
cedure being approved by the local Research Ethics
Committee. No other procedure, except those required for
treating infertility, was carried out. The decisions to
include or exclude r-LH in the ovarian stimulation fol-
lowed the protocol of the Clinic: until July 2006, no cycles
included r-LH; after this date, all cycles included r-LH.
Routinely, first pituitary down-regulation was established
with nafarelin acetate at the dose of 400 μg/day (Synarel®;
Pharmacia, SP, Brazil.), started during the second phase of
the previous cycle. After 14 days of treatment with GnRH-
a, r-FSH (Gonal F®; Serono, SP, Brazil) was started. Then
the patients were divided into two groups matched by age:
-Group I (n = 122): r-FSH was administered at the fixed
dose of 150–225 IU for a period of 7 days. On the 8th day
of ovarian stimulation, follicular development started to
be monitored by vaginal ultrasound only, and r-FSH
doses were adapted according to ovarian response. No r-
LH was used.
-Group II (n = 122): r-LH (Luveris®, Serono, SP, Brazil)
was administered at 75 IU/day with an r-FSH fixed dose
(150–225 IU) for a period of 7 days. On the 8th day of
ovarian stimulation, the r-FSH dose was adapted accord-
ing to ovarian response, and r-LH supplementation was
increased to 150 IU/day when one or more follicles meas-
uring ≥ 10 mm in diameter were found.
Then, when one or more follicles measuring ≥ 17 mm
were observed, r-hCG (Ovidrel®, Serono, SP, Brazil) was
administered at the dose of 250 μg.
Oocytes were retrieved from the follicles by ultrasound
guided transvaginal puncture 36–38 h after r-hCG admin-
istration. The oocytes retrieved were stripped from the
cumulus-corona cells utilizing a solution containing 40
IU/ml of hyaluronidase (Irvine Scientific, USA) and the
denuded oocytes were classified by maturity based on
morphological criteria. Oocytes were incubated in P1 with
10% HAS (Irvine Scientific, USA) until the moment for
ICSI. Discontinuous gradients of Isolate® (Irvine Scientific,
USA) were used to separate spermatozoa from the seminal
fluid in the 40–90% fractions. ICSI were performed as
described previously [8,9].
Embryos were routinely transferred after 48 h in culture
with a Frydman catheter (Frydman® Classic Catheter 4.5
CCD Laboratoire C.C.D; Paris, France) guided by abdom-
inal ultrasound using a 3.5 MHz convex transducer (AlokaReproductive Biology and Endocrinology 2009, 7:58 http://www.rbej.com/content/7/1/58
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SSD-1100; Aloka Co. Ltd, Tokyo, Japan). Supernumerary
embryos were cryopreserved at the end of the 2nd day. The
same physician performed all transfers. All patients
received luteal phase supplementation with vaginal natu-
ral progesterone (Utrogestan®; Farmoquímica, RJ, Brazil).
For the freezing-thawing process, an embryo freeze-thaw
media kit (Irvine Scientific, USA) was used. Frozen
thawed embryo transfer was performed after assessment
of embryo cleavage, when the division of at least one of
the blastomeres was observed after 24 hours of culturing.
Only one protocol was used for transferring frozen-
thawed embryos. Estradiol valerate (Cicloprimogyna®;
Schering, SP, Brazil) was administered from the first day
to day 14 of the cycle at a daily dose of 6 mg. Progesterone
(Utrogestan®; Farmoquímica, RJ, Brazil) was also intro-
duced vaginally on day 14 at 400 mg/day, as long as
endometrial thickness was ≥ 6 mm [10] and was increased
to a daily dose of 800 mg on the day of embryo transfer.
Thawing was performed on day 5 of progesterone treat-
ment and embryos were transferred on day 6. The same
physician performed all transfers.
Data were analyzed using InStat version 3.0 (GraphPad
Software, San Diego, California, USA) on a Macintosh
computer (Apple Computer Inc., Cupertino, California,
USA). The Student's t, Mann-Whitney and x2 tests were
utilized when appropriate. The level of significance was
set at P < 0.05.
Results
The general characteristics of the study population are
summarized in Table 1. There were 122 subjects assigned
to each of the two treatment groups. The age of patients in
Group I (32.7 ± 3.7 y) was equal (P = 0.99) to that of
patients in Group II (32.7 ± 3.7 y). An equal distribution
(P  > 0.05) of the other main characteristics was also
observed for groups I and II.
The total dose of r-FSH was similar (P = 0.13) between
Group I (2181 ± 719 IU) and Group II (2032 ± 651 IU).
The number of oocytes collected from Group I (9.3 ± 4.7)
was statistically lower (P = 0.036) than that in Group II
(10.9 ± 5.9). In addition, the number of oocytes in met-
aphase II was significantly lower (P = 0.0014) in Group I
(6.7 ± 4.1) in relation to Group II (8.5 ± 4.6), but the
number of immature oocytes was not significantly differ-
ent between the two groups (Group I:2.6 ± 2.7; Group
II:2.4 ± 2.8, P = 0.12). Also, the fertilization rate was sig-
nificantly lower (P = 0.017) in Group I (66.2%, 634/958)
than in Group II (71.1%, 835/1175). The mean number
of embryos produced per cycle was statistically lower (P =
0.0092) in Group I (5.4 ± 3.7) than in Group II (6.5 ±
3.0). The mean number of embryos transferred from
Group I (2.0 ± 0.8) was similar (P = 0.42) to that from
Group II (2.0 ± 0.5). The mean number of embryos frozen
per cycle was statistically lower (P = 0.0008) in Group I
(3.0 ± 3.6) than in Group II (4.4 ± 3.8). The implantation
rate was similar (P = 0.17) between Group I (17.9%) and
Table 1: General characteristics of the study population
Total Group I
(no r-LH)
Group II
(r-LH)
P
Female age 32.7 ± 3.7 32.7 ± 3.7 32.7 ± 3.7 ns
Distribution of females
<30 y 19.7 (48) 19.7 (24) 19.7 (24) ns
30–35 y 54.1(132) 54.1 (66) 54.1 (66)
36–39 y 26.2 (61) 26.2 (32) 26.2 (32)
Male age 37.2 ± 6.8 37.2 ± 6.3 37.1 ± 7.2 ns
Infertility Factor
-Male factor 45.5(111) 48.4 (59) 42.6 (52) ns
-Idiopathic 16.8 (41) 14.0 (17) 19.7 (24)
-Endometriosis 13.5 (33) 9.8 (12) 17.2 (21)
-Tubal–peritoneal 13.5 (33) 17.2 (21) 9.8 (12)
-Tubal–peritoneal+endometriosis 4.9 (12) 5.7 (7) 4.1 (5)
-Tubal–peritoneal + male 2.9 (7) 3.3 (4) 2.5 (3)
-Endometriosis + male 2.9 (7) 1.6 (2) 4.1 (5)
BMI (kg/m2) 23.2 ± 2.9 23.1 ± 3.0 23.4 ± 2.9 ns
Infertility
-Primary 77 (188) 77.9 (95) 76.2 (93) ns
-Secondary 23 (56) 22.1 (27) 23.8 (29)
Duration of infertility (y) 4.6 ± 3.5 5.2 ± 4.1 4.0 ± 3.0 ns
basal FSH (mUI/ml) 5.9 ± 2.6 5.2 ± 1.9 6.4 ± 3.1 ns
basal LH (mUI/ml) 5.4 ± 3.4 4.8 ± 2.6 6.1 ± 4.1 ns
basal Estradiol (pg/ml) 47.7 ± 23.5 48.3 ± 28.8 47.1 ± 23.6 ns
ns: not significant
Values are mean ± SD or %(n)Reproductive Biology and Endocrinology 2009, 7:58 http://www.rbej.com/content/7/1/58
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Group II (23.2%). The pregnancy rate per patient, cycle
and transfer were not statistically significant different for
Group I (29.5%, 29.5%, and 31.6%, respectively) com-
pared with those of Group II (33.6%, 33.6%, and 34.4%,
respectively). The miscarriage rate was similar (P = 0.90)
between Group I (11.1%) and Group II (14.6%). The
cumulative live birth rate per cycle was statically similar (P
= 0.65) between the two groups (Group I: 23.8%; Group
II: 27%). Table 2 displays these data.
Table 3 shows laboratory and clinical data with respect to
the freezing-thawing process. The cumulative implanta-
tion rate (fresh + thawed embryos) was significantly lower
(P = 0.04) in Group I (14.7%) than in Group II (20.6%).
At the moment, the cumulative pregnancy rate per transfer
and patient (fresh + thawed) are similar (P = 0.31 and P =
0.24 respectively) for Group I (27.9% and 37.7%, respec-
tively) and Group II (33.5% and 45.6%, respectively).
Also, the cumulative live birth rate per cycle and patient
were statically similar (P = 0.54 and P = 0.57, respectively)
between the two groups (per cycle:Group I: 20.2%, Group
II: 23.5%; per patient: Group I: 28.7%, Group II: 32.8%)
When age subgroup analyses comparing results from
women aged ≤ 35 y with those >35 y were carried out
(Table 4), it was observed that the difference found
between the groups with and without r-LH was due pri-
marily to the results in the subgroups of patients aged ≤ 35
y. The number of oocytes in metaphase II was significantly
lower (P = 0.003) in the subgroup without r-LH aged ≤ 35
y (7.4 ± 4.3) than in the subgroup with r-LH aged ≤ 35 y
(9.3 ± 4.5). Also, the fertilization rate was significantly
lower (P = 0.04) in the subgroup without r-LH aged ≤ 35
y (67.8%, 533/786) than in the one with r-LH aged ≤ 35
y (72.5%, 687/948). In addition, the mean number of
embryos produced per cycle was statistically lower (P =
0.003) in the subgroup ≤ 35 y without r-LH (5.9 ± 3.7)
than the one of the same age range with r-LH (7.6 ± 4.1).
The only exception was the mean number of embryos fro-
zen per cycle which presented a difference both between
the subgroups aged ≤ 35 y (subgroup without r-LH:3.7 ±
3.9; subgroup with r-LH:5.0 ± 3.8, P = 0.008) and between
the subgroups aged >35 y (subgroup without r-LH:1.1 ±
2.1; subgroup with r-LH:2.8 ± 3.3, P = 0.03). The other
evaluations did not show any difference among the sub-
groups. Table 5 shows laboratory and clinical data with
respect to the freezing-thawing process in relation to sub-
groups. Again, the only difference found was in the cumu-
lative implantation rate (fresh + thawed embryos), which
was significantly lower (P = 0.008) in the subgroup with-
out r-LH aged ≤ 35 y (14.2%) when compared to the sub-
group including the same age range with r-LH (23.2%).
The other evaluations found no differences among the
subgroups.
Discussion
The validity of the two-cell, two-gonadotrophin hypothe-
sis, which suggests that both LH and FSH are required for
ovarian steroidogenesis in a gonadotrophin-deficient
population (World Health Organization classification I),
is clear. However, there is still considerable controversy
on the need for additional LH supplementation in cycles
of assisted reproduction techniques using GnRH-a [11].
Table 2: Clinical and laboratory results of the fresh ICSI procedures.
Group I
(No r-LH)
Group II
(r-LH)
p-value
Patients (n) 122 122
Cycles (n) 122 122
Transfers (n) 114 119
Total dose r-FSH (IU) 2181 ± 719 2032 ± 651 ns
Total dose r-LH (IU) ------ 1048 ± 262
Retrieved oocytes (n) 9.3 ± 4.7 10.9 ± 5.9 0.036
Immature oocytes (n) 2.6 ± 2.7 2.4 ± 2.8 ns
Metaphase II oocytes (n) 6.7 ± 4.1 8.5 ± 4.6 0.0014
Fertilization rate 66.2% 71.1% 0.017
Embryos/cycle(n) 5.4 ± 3.7 6.5 ± 3.0 0.0092
Embryos transferred(n) 2.0 ± 0.8 2.0 ± 0.5 ns
Frozen embryos/cycle(n) 3.0 ± 3.6 4.4 ± 3.8 0.0008
Implantation rate 17.9% 23.2% ns
Pregnancy rate
-per patient 29.5% 33.6% ns
-per transfer 31.6% 34.4% ns
Miscarriage rate 11.1% 14.6% ns
Live birth/patient (or started cycle) 23.8% 27.0% ns
ns: not significantReproductive Biology and Endocrinology 2009, 7:58 http://www.rbej.com/content/7/1/58
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It has been widely demonstrated that, during ovarian
stimulation with FSH and concomitant administration of
a GnRH-a, the endogenous LH level decreases, reaching its
lowest value during the late stimulation phase. Thus, it
would seem logical that if LH supplementation is to show
any benefit, it would occur at least in the late follicular
phase.
Oliveira et al. [12] compared, by meta-analysis, the effi-
cacy of r-LH supplementation for controlled ovarian stim-
ulation in r-FSH and GnRH-a protocol. The data showed
fewer days of stimulation, less total amount of r-FSH
administered and higher serum estradiol levels on the day
of hCG administration with the r-LH supplementation
protocol. However, differences were not observed in the
number of oocytes retrieved, number of mature oocytes,
and clinical pregnancy per oocyte retrieved, implantation
or miscarriage rates. Moreover, in this meta-analysis, all
randomized controlled trials started r-LH after 6 days of r-
FSH.
On the other hand, our data showed more significant pos-
itive effects of r-LH: a larger number of retrieved oocytes
and oocytes in metaphase II, elevated fertilization rate and
Table 3: Clinical and laboratory characteristics of the frozen/thawed ICSI procedures
Group I
(no r-H)
Group II
(r-LH)
p-value
Patients (frozen + thawed) (n) 43 40
Transfers (n) 51 48
Thawed and transferred embryos (n) 128 114
Implantation rate/thawed embryos 8.6% 15% ns
Pregnancy rate
-per thawed embryo transfer 19.6% 31.2% ns
-per patient 23.2% 37.5% ns
Cumulative implantation rate (fresh + thawed) 14.7% 20.6% 0.04
Cumulative pregnancy rate (fresh+ thawed)
-per transfer 27.9% 33.5% ns
-per patient 37.7% 45.9% ns
Cumulative live births/(fresh+ thawed)
-per started cycle 20.2% 23.5% ns
-per patient 28.7% 32.8% ns
ns: not significant
Table 4: Female age subgroup analysis ≤ 35 years vs. >35 years.
Group I
(No r-LH)
Group II
(r-LH)
≤ 35 years > 35 years ≤ 35 years > 35 years
Patients 90 32 90 32
Cycles 90 32 90 32
T r a n s f e r s 8 43 08 93 0
Total dose r-FSH (IU) 1976.7 ± 583.3 2756.3 ± 760.6 1873.6 ± 546.2 2477.3 ± 721.8
Total dose r-LH (IU) ------ ------ 1034.2 ± 245.9 1087.5 ± 302.4
Retrieved oocytes 10.4 ± 4.7 6.4 ± 3.4 11.9 ± 5.8 8.1 ± 5.2
Immature oocytes 3.0 ± 2.9 1.6 ± 1.4 2.6 ± 2.9 1.9 ± 2.5
Metaphase II Oocyte 7.4 ± 4.3a 4.8 ± 3.0 9.3 ± 4.5a 6.7 ± 4.5
Fertilization rate 67.8%b 58.7% 72.5%b 65.2%
Embryos/cycle (n) 5.9 ± 3.7c 3.2 ± 2.0 7.6 ± 4.1c 4.6 ± 3.2
embryos transferred (n) 2.0 ± 0.7 2.1 ± 0.9 2.0 ± 0.3 2.0 ± 0.9
frozen embryos per cycle(n) 3.7 ± 3.9d 1.1 ± 2.1e 5.0 ± 3.8d 2.8 ± 3.3e
Implantation rate 18.3% 16.7% 25.8% 15.4%
Pregnancy rate
-per patient 27.8% 34.4% 36.7% 25%
-per transfer 29.8% 36.7% 37.1% 26.7%
Miscarriage rate 8% 18.2% 15.2% 12.5%
Live birth/patient (or started cycle 24.4% 21.9% 28.9% 21.9%
Clinical and laboratory results of the fresh ICSI procedures.
a-b-c-d-e Values within rows with the same superscript letter were significantly different: P < 0.05Reproductive Biology and Endocrinology 2009, 7:58 http://www.rbej.com/content/7/1/58
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increased numbers of embryos frozen and produced by
cycle. Nevertheless, r-LH supplementation (75UI) was
started with r-FSH protocol at the beginning of the follic-
ular phase. Normally, LH contributes to the ovarian stim-
ulation process when granulosa cells of the follicles
become receptive to LH, and follicles ≥ 10 mm with LH
receptors keep growing due to decreasing FSH concentra-
tions in the mid to late follicular phase [13]. Willis et al.
[14] showed that granulosa cells from ovulatory patients
(with either normal ovaries or polycystic ovaries)
responded to LH once follicles reached 9.5/10 mm. In
contrast, granulosa cells from anovulatory women with
polycystic ovaries responded to LH in follicles smaller
than 4 mm. Thus, the precocity of r-LH administration
could be beneficial for follicles that are ≥ 10 mm during
the first days of r-FSH use (day 1 to day 7). For this reason,
we opted for early LH initiation in the present study (first
day of stimulation).
However, the LH requirement for the maintenance of fol-
licular steroidogenesis is likely to be low because <1% of
follicular receptors need to be occupied to permit normal
steroidogenesis [15]. The number of patients with pro-
found LH depression (after GnRH-a) differs among the
published studies [16]. Severe LH deficiency was reported
as 6% by Loumaye et al. [17], 40% by Fleming et al. [18]
and 49% by Westegaard et al. [19], with each research
group using different criteria and assays for definition.
Westergaad et al. [19] determined that very low LH con-
centrations (< 0.5 IU/l) can also be detrimental to fertility
outcomes, showing that this group of patients suffers
more often from early pregnancy loss when compared
with patients having normal LH concentrations (> 0.5 IU/
l) (45% versus 9%, respectively). Ruvolo et al. [20]
showed data suggesting that supplementation with r-LH
during the follicular phase improves some laboratory
parameters, and, in particular, seems to significantly
reduce the number of immature oocytes collected after
pick-up. The apoptosis rate in cumulus cells was higher in
the control group than in the r-LH group. This finding
may represent a situation in which, despite the presence of
a low quantity of this hormone because of the paracrine
effect mediated by secreting factors in the theca and
oocyte cells, the cumulus cells are preserved from apopto-
sis. By maintaining their physiological function for a
longer time, cumulus cells are better able to support
nuclear and cytoplasmic maturation of the oocyte until
ovulation. Bosco et al. [21] demonstrated that apoptosis
in human oocytes determines fertilization failure after
ICSI. If the activation of apoptosis in the oocyte is regu-
lated by molecular signals coming from cumulus cells
through gap junctions, the lower apoptotic rate in cumu-
lus cells would be an indicator of good oocyte quality in
relation to a greater capacity to be fertilized and to pro-
duce embryos of higher potential.
Therefore, there is a need for further clinical research to
establish appropriate clinical criteria for LH supplementa-
tion. FSH plays a crucial role in recruitment, selection, and
dominance, while LH contributes to dominance, matura-
tion, and ovulation. However, Dumerin et al. [22] showed
that pretreatment with r-LH followed by r-FSH in women
who were profoundly down-regulated by GnRH agonist
(Depot) increased small antral follicles and normally fer-
tilized (2PN) embryos. This suggests possible beneficial
effects of up-regulated androgen upon follicular metabo-
lism and an early action. On the other hand, there is basic,
experimental and clinical evidence unequivocally indicat-
Table 5: Female age subgroup analysis ≤ 35 years vs. > 35 years.
Group I
(no r-H)
Group II
(r-LH)
≤ 35 years > 35 years ≤ 35 years > 35 years
Patients (frozen + thawed) 36 7 30 10
Transfers (n) 44 7 37 11
Thawed and transferred embryos (n) 115 13 85 29
Implantation rate per thawed embryos 7.8% 15.4% 17.6% 6.9%
Pregnancy rate
-per thawed embryo transfer 18.2% 28.6% 35.1% 18.2%
-per patient 22.2% 28.6% 43.3% 10%
Cumulative implantation rate (fresh + thawed) 14.2%a 16.4% 23.2%a 14.9%
Cumulative pregnancy rate (fresh+thawed)
-per transfer 25.8% 35.1% 36.5% 24.4%
-per patient 36.7% 40.6% 51.1% 31.2%
Cumulative live birth (fresh+thawed)
-per started cycle 20.1% 20.5% 25.2% 18.6%
-per patient 30% 25% 35.5% 25%
Clinical and laboratory characteristics of the frozen/thawed ICSI procedures.
a P < 0.05Reproductive Biology and Endocrinology 2009, 7:58 http://www.rbej.com/content/7/1/58
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ing that ovarian follicles have development-related
requirements for stimulation by LH. There is a "thresh-
old" for LH requirements during folliculogenesis [23].
Whereas each follicle has a threshold beyond which it
must be stimulated by FSH to initiate preovulatory devel-
opment, it may also have a "ceiling" below which it
should be stimulated by LH. Therefore, LH concentrations
should be neither too high nor too low during stimula-
tion of ovulation in order to not compromise reproduc-
tive performance.
On the other hand, multiple novel roles of LH have been
proposed and it has been postulated that LH may affect
IVF/ICSI results both by determining oocyte quality and
by influencing uterine receptivity via ovarian estradiol
secretion or through direct effects on the endometrium,
myometrium, and uterine artery and vein [24-26]. In
addition, our results from fresh embryo transfer with
respect to implantation rates and clinical pregnancies are
superior, but not significantly greater in the r-LH supple-
mentation group. However, the cumulative implantation
rate (fresh + thawed embryos) is significantly higher in the
patients with r-LH supplementation.
An age subgroup analysis in order to detect a beneficial
effect of LH supplementation in a particular age range was
carried out, as had been done in some studies showing a
positive result of this practice in patients >35 y[27,28].
Nevertheless, our analysis showed a diverse result, evi-
dencing greater benefit from the use of r-LH in patients
aged ≤ 35 y. However, the sample size is too small, partic-
ularly in the patient subgroup >35 y (total 64 patients), to
draw conclusions on this point with sufficient statistical
power.
We acknowledge the limitations of the current study,
firstly the difference in the time at which the two groups
underwent their respective procedures. It is impossible to
control for increased experience and potential improve-
ments in the clinical and laboratory settings that could
influence the results in such a study. However, besides the
laboratory procedures having been exactly the same in the
two groups, the responsible laboratory staff had already
accumulated vast experience, having worked with IVF/
ICSI for more than 10 years before the commencement of
the study. Second, although the patients were matched by
age, the make-up of patients by diagnoses in each group
was quite diverse and this in itself could have affected
some of the differences observed between groups I and II.
However, it should be emphasized that the statistical
analysis did not show any difference between the two
groups. Finally, to evaluate the efficacy of the two proto-
cols considering both fresh and thawed ET, more clinical
endpoints such as live birth rate per started cycle present
greater importance than the started cycle implantation
rate. However, it should be noted that avoiding a beta-
type error when assessing a difference between the two
study groups (maintaining the same rates of live birth rate
herein described), with a power of 80% and a level of sig-
nificance of 5%, would require a sample size of more the
2500 cycles in each group.
In conclusion, the data of the present study support r-LH
supplementation in ovarian stimulation protocols with r-
FSH and GnRH-a for assisted reproduction treatment.
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